Bringing J&J Innovation

to LifeCADTH MeetingAPRIL, 2015

Innovation Centers

‘The patients are waiting!’

- Dr. Paul Janssen

ONCE EVERY

Someone dies from diabetes or

related medical issues

8 SECONDS

• The diabetes epidemic is a “secondary epidemic” primarily following the

epidemic in obesity.

– If the obesity epidemic were to resolve, or disappear, type 2 diabetes would

largely disappear as well, even without active diabetes-specific interventions.

– Surgical interventions largely aimed at treatment of obesity ( i.e. bariatric

surgery) often result in “cure” of early diabetes or remission or regression, or

significant clinical improvement of later disease.

• The lipocentric view of diabetes suggests the abnormalities in excessive

adipose tissue accumulation and ectopic deposition of fatty acids

largely drives both insulin resistance and decrease insulin secretion

contributing to the development of diabetes.

4

The Diabetes Epidemic Will Strain the Capacity of Healthcare Systems if Left Unchecked

5

Intervention at the Pre-diabetic Stage Provides an Opportunity to Change the Course of DiseasePersistent Insulin Resistance and Progressive β-cell Decline

Intervention of Pre-Diabetes Will Require Identification, Lifestyle Changes, and Treatment

• Biomarkers that aid in the identification of individuals that are

most likely to progress to Type 2 Diabetes

• Education and other methods to increase compliance towards

healthy lifestyle changes

• Development of therapies that focus on the root causes of

diabetes (e.g. insulin resistance) which can delay/prevent the

onset of frank diabetes

– insulin sensitizers, b cell regeneration

‘The patients are waiting!’

- Dr. Paul Janssen

One person dies of melanoma EVERY HOUR

• The underlying pathways that lead to proliferative dysregulation are

continuing to be better understood

• Targeted therapies are moving cancer treatment towards more

individually tailored treatments

• Combinations of existing and novel therapies are being explored to

increase 5yr survival times across a number of cancer types

• Therapies designed to evoke powerful immune responses towards

tumors are dramatically changing outcomes in a subset of late-stage

tumor types

8

Increased Understanding of Oncogenic Drivers and the Rise of Immuno-oncology is Changing Cancer Treatment

Immuno-Oncology: An Exciting New Approach for Patients Living with Cancer

9

Confidential

Reactivation and redirection of patient’s

immune response towards malignant cells

Four Approaches

1. T Cell Checkpoints

• PD1 and PD-L1 antibodies (BMS,

Merck, Genentech, AZ/Medimmune)

• Ipilumumab (BMS)

2. T Cell Redirection

• Blinotumumab (Amgen BiTE)

3. Chimeric Antigen Receptor T cells

• Infusion of engineered T cells

4. Vaccines

The Future Treatment Paradigms in Oncology will Continue to Be More Personalized

• Approaches to rationally guide combination strategies

• Next generation immunotherapy agents/mechanisms

• Mechanisms of resistance to emerging immunotherapy (PD1, PDL1, CTLA4)

• Novel tumor antigen ID approaches and vaccine technologies

• Identification of pre-disposing mutations and subsequent prevention of disease

10

Confidential

‘The patients are waiting!’

- Dr. Paul Janssen

1 in 3 Seniors Who Die Each Year Have Been Diagnosed WithAlzheimer’s or AnotherDementia

Alzheimer’s Disease Presents a Staggering Problem to Ageing Individuals, their Caregivers, and Society

12

• Only one in four people with Alzheimer’s have been diagnosed (Alzheimer’s

Disease International)

• The direct and indirect costs of caring for people with Alzheimer’s and

dementia in the Canada is approximately $33B per year, worldwide it is greater

than $600B (Alzheimer’s Society Canada)

• One in five Canadians aged 45 and older provides some form of care to

seniors living with long-term health problems - in 2011, family caregivers spent

in excess of 444 million unpaid hours looking after someone with cognitive

impairment, including dementia. (Alzheimer’s Society Canada)

• There are currently no treatments that result in modification of the course of

disease

The Challenges Presented by Alzheimer’s Disease Include Insufficient and Late Diagnosis, as Well as a Lack of Treatment Options

13

• Brains of individuals with Alzheimer’s

Disease are characterized by the

presence of plaques (beta-amyloid) and

tangles (tau)

• The presence of plaques and tangles can

proceed the development of symptoms

• Both beta-amyloid and tau are the focus

of a number of novel therapeutic

approaches

Image credit: Jannis Productions. Rebekah Fredenburg, computer animation; Stacy Jannis, illustration/art direction

The Future Treatment of Alzheimer’s Disease Will be Dependent on Identification of Individuals Early in Disease and Generation of Effective Treatments

14

• More sensitive and specific methods for determining which individuals will go

on to develop disease

• Beta-amyloid targeted treatments have had a challenging clinical history,

although there are still many efforts underway that are hopeful

• Tau-based approaches are currently moving towards later-stage clinical testing

and may provide new treatment options for people living with disease

• The evolving understanding of the brain biology and disease pathogenesis will

provide the field with new insights to disease prevention, management, and

treatment

• Public-private partnerships will be essential in the development of both new

diagnostics as well as therapeutics

Tapping Innovation in Canada

Boston IC

Janssen Canada

Innovation Incubator

Consortium

Montreal

Boston IC

Janssen Canada

JJMP

Innovation Incubator

Dedicated Fund

Toronto

Janssen Canada

Alberta Diabetes Foundation

Government of Alberta

California IC Judges

$600k

Dedicated Fund

Edmonton

Janssen Canada

Government of British Columbia

Government of Alberta

California IC representatives

$1m

Dedicated Fund

Vancouver

California IC

Janssen Canada

Government of Canada

National Contest

Canada-wide

California IC

Janssen Canada

Neuroscience TA

Dedicated Fund

Toronto

Janssen Pharmaceuticals NV

Industry Consortium

Toronto

BetaLogics

Janssen R&D

Industry Consortium

Toronto

Thank You !!